A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/12/2019
Start Date:September 23, 2015
End Date:March 31, 2020
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)

The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended
phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study,
and to assess the anti-tumor activity and safety of INC280 alone, and in combination with
erlotinib, versus platinum with pemetrexed in the Phase II of this study, in adult patients
with EGFR mutated, cMET amplified, advanced/metastatic non-small cell lung cancer with
acquired resistance to prior EGFR TKI.

The decision was taken to halt study enrollment with Cohort #3 in Phase 1b. Therefore,
activities for the planned Phase 2 were not initiated.

This decision to stop further development of this combination was taken due to the challenge
for enrollment in this very rare patient population along with the rapidly evolving disease
landscape setting.

Inclusion Criteria:

- Locally advanced or metastatic NSCLC

- EGFR mutation (L858R and /or ex19del)

- cMET amplification by FISH (GCN ≥ 6),

- Acquired resistance to EGFR TKI (1st or 2nd génération)

- ECOG performance status (PS) ≤ 1.

Exclusion Criteria:

- Prior treatment with 3rd generation TKI

- PhaseII : Prior treatment with any of the following agents:

- Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.

- Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.

- Platinum-based chemotherapy as first line treatment
We found this trial at
10
sites
Detroit, Michigan 48201
Principal Investigator: Shirish M. Gadgeel
Phone: 313-576-9454
?
mi
from
Detroit, MI
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Christina Baik
Phone: 206-288-2056
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Taofeek K. Owonikoko
Phone: 404-778-4576
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Brussel,
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Igor Rybkin
Phone: 313-916-1784
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Fairfax, Virginia 22031
Principal Investigator: Alexander Spira
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
Principal Investigator: Konstantin Dragnev
Phone: 603-650-4428
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Los Angeles, California 90017
Principal Investigator: Boris Bagdasarian
Phone: 213-977-1214
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Roy Steven Herbst
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Sai-Hong Ignatius Ou
?
mi
from
Orange, CA
Click here to add this to my saved trials